Averna Therapeutics
PrivateLast Round
Series A
Jun 25, 2024
Total Funding Raised
$82M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Averna Therapeutics is a biotechnology company that develops RNA/lipid nanoparticle-based genomic medicines to durably and safely treat a broad range of diseases, including genetic disorders, cancer, and autoimmune conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Averna Therapeutics Comparables
Compare Averna Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Stylus Medicine | 81% | |
| Ensoma | 80% | |
| Tessera Therapeutics | 79% |
Averna Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 25, 2024 |
Averna Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deep Insight | Series A |
| Innovation Endeavors | Series A |
| OrbiMed | Series A, Seed |
| Invus Opportunities | Series A |
| Arc Ventures | Series A |
| Delos Capital Partners | Series A |
| Invus | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Open roles increased to 28, 2.3x the trailing average.
- Jul 24, 2026
Monthly visitors increased 390% MoM, reaching 7.7K.
Averna Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Averna Therapeutics's valuation, stock price, and market status.
Is Exsilio a public or private company?
Exsilio is a private company.
What is the current stock price of Exsilio?
Exsilio is a private company with no public stock price. No recent secondary market data is available.
How much is Exsilio worth (valuation)?
Valuation information for Exsilio is not publicly available.
Can I buy Exsilio stock?
Exsilio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Exsilio's last funding round?
Exsilio's most recent funding round was Series A on June 25, 2024.
Who are the main investors in Exsilio?
Key investors in Exsilio include OrbiMed, Delos Capital Partners.
Will Exsilio IPO soon?
No public IPO plans have been announced for Exsilio.
How can I track Exsilio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Exsilio's secondary market activity and sign up for updates.